Ceftonus powder for solution for injection

País: Armênia

Língua: inglês

Origem: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Ingredientes ativos:

ceftriaxone (ceftriaxone sodium)

Disponível em:

Panpharma Z.I.

Código ATC:

J01DD04

DCI (Denominação Comum Internacional):

ceftriaxone (ceftriaxone sodium)

Dosagem:

1000mg

Forma farmacêutica:

powder for solution for injection

Unidades em pacote:

(25) glass vial

Tipo de prescrição:

Prescription

Status de autorização:

Registered

Data de autorização:

2018-01-10

Características técnicas

Company: PANPHARMA
Product:
Ceftonus 1 g, Powder for solution for injection
Module1
1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
CEFTONUS, 1 G, POWDER FOR SOLUTION FOR INJECTION
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Ceftriaxone
As ceftriaxone sodium
....................................................................................................................................
1 g
For one vial flacon.
Excipient with a known effect: sodium (83 mg per vial).
For the complete list of excipients, please see section 6.1.
3. PHARMACEUTICAL FORM
Powder for solution for injection or for infusion.
4.CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Ceftriaxone is indicated for the treatment of the following infections
in adults and children including term
neonates (from birth):
Bacterial Meningitis
Community acquired pneumonia
Hospital acquired pneumonia
Acute otitis media
Intra-abdominal infections
Complicated urinary tract infections (including pyelonephritis)
Infections of bones and joints
Complicated skin and soft tissue infections
Gonorrhoea
Syphilis
Bacterial endocarditis.
Ceftriaxone may be used:

For treatment of acute exacerbations of chronic obstructive pulmonary
disease in adults.

For treatment of disseminated Lyme borreliosis (early (stage II) and
late (stage III)) in adults and
children including neonates from 15 days of age.

For Pre-operative prophylaxis of surgical site infections

In the management of neutropenic patients with fever that is suspected
to be due to a bacterial
infection.

In the treatment of patients with bacteraemia that occurs in
association with, or is suspected to be
associated with, any of the infections listed above.
Ceftriaxone should be co-administered with other antibacterial agents
whenever the possible range of causative
bacteria would not fall within its spectrum (see section 4.4).
Company: PANPHARMA
Product:
Ceftonus 1 g, Powder for solution for injection
Module1
2
Consideration should be given to official guidelines on the
appro